The Food and Drug Administration rejected ImClone 's 2001 application to sell Erbitux , citing shoddy research .
The U.S. Food and Drug Administration rejected ImClone 's original application in December 2001 , saying the trial had been sloppily conducted .
A White House spokesman added that Iran had " one last chance " to comply with its disarmament obligations .